Trump Buys SpaceX Shares After Record IPO 
BOJ’s Himino Signals Timely Rate Hikes as Inflation Risks Rise 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Asian Currencies Slip as Dollar Rebounds on Iran Sanctions 
Asian Stocks Rebound as Oil Prices Fall, Nvidia Earnings in Focus 
Japan Eyes Tax Changes to Curb Condo Speculation 
Tesla Raises Cybertruck Prices by $5,000 in US 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Asian Stocks Slip Ahead of Nvidia Earnings and US Inflation Data 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Qatar LNG Exports Plunge 96% as U.S.-Iran War Disrupts Gulf Energy Trade 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Oil Prices Fall as Middle East Ceasefire Hopes Rise 
Add as a preferred source on Google
Lotte Biologics has inked a memorandum of understanding (MOU) with Roche Diagnostics to bolster its Contract Development and Manufacturing Organization (CDMO) capabilities. This collaboration signifies major diagnostics, hardware, and automation advancements for Lotte's upcoming Korean production plants.
On Wednesday, Aug. 9, Lotte Biologics said it will work with Roche Diagnostics to improve the productivity and quality of its productions. The company said they would also team up to establish hardware and automation systems for Lotte's upcoming production plants in Korea, as per Korea Joongang Daily.
The MOU was signed at Roche Diagnostics CustomBiotech Center in Penzberg, Germany. Lotte Biologics' chief executive officer, Richard Lee; Roche Diagnostics CustomBiotech's vice president, Rainer Mueller; and Roche Diagnostics Korea's general manager, Kit Tang, were all present at the signing ceremony.
With the deal in place, Lotte Biologics aims to amplify its credibility with future global clients. The agreement will also serve as the forefront to underpin and shore up Roche Diagnostics' supply network in the Asian market. This will also give better treatment access to patients around the world.
"Through this MOU, we plan to enhance the production process capabilities of our Korean Mega Plant in collaboration with Roche Diagnostics," Lotte Biologics chief Richard Lee said in a press release. "Through synergy with Roche Diagnostics, an industry leader in the in vitro diagnostic field, LOTTE hopes to improve the efficiency of its operations at the forthcoming Korean Mega Plant, simultaneously augmenting the quality of our manufacturing and fulfilling customer needs."
Finally, Business Korea reported that Lotte Biologics and Roche Diagnostics will cooperate on various business fronts, including installing automation systems at the former's Mega Plants that will be built in Korea. The latter will also provide technical consulting and equipment support for the facilities.
Photo by: Lotte Biologics Newsroom
